Reverse-phase chromatography is one of the most widely applied separation strategies in pharmaceutical discovery, chemical development, peptide research, impurity investigation, and compound purification. For drug development teams, the major challenge is rarely whether RP chromatography can separate a target molecule, but how rapidly a robust, selective, scalable, and information-rich method can be established for complex samples. BOC Sciences provides comprehensive reverse-phase chromatography services covering analytical method development, RP-HPLC and UHPLC testing, preparative purification, impurity isolation, peptide and oligonucleotide separation, fraction profiling, and method transfer support. By integrating column chemistry screening, mobile-phase optimization, gradient design, UV/MS-based detection, and fraction collection strategies, we help pharmaceutical researchers, medicinal chemists, analytical scientists, and project managers obtain reliable chromatographic data and high-value purified materials for downstream research.
BOC Sciences develops tailored reverse-phase methods through systematic column, mobile phase, pH, temperature, and gradient screening. Our HPLC testing platform supports reliable separation of APIs, intermediates, degradation products, peptides, and structurally related impurities.
For projects requiring faster turnaround, sharper peaks, and improved resolution, our UHPLC testing capabilities enable high-efficiency separations with reduced sample consumption and enhanced sensitivity for complex pharmaceutical matrices.
Our preparative HPLC services support the isolation of target compounds from milligram to gram-level projects, enabling medicinal chemistry, reference material preparation, peptide purification, and impurity enrichment.
BOC Sciences integrates reverse-phase separation with impurity isolation and identification workflows to help clients understand unknown peaks, process-related impurities, degradants, and by-products in drug development samples.
BOC Sciences delivers customized reverse-phase chromatography solutions for complex molecules, challenging impurities, peptide sequences, and development-stage pharmaceutical samples.
We evaluate multiple reversed-phase stationary phases, including C18, C8, phenyl-hexyl, polar-embedded, and wide-pore materials, to identify the optimal balance between retention, selectivity, peak shape, and compatibility with each molecular class.
Our scientists refine gradient slope, initial hold, organic modifier strength, re-equilibration time, and flow rate to improve resolution for closely eluting peaks while maintaining practical run times for routine project use.
Through LC-MS testing, we connect chromatographic retention behavior with molecular mass information, helping clients assign target peaks, track impurities, and prioritize fractions for further analysis.
When unknowns require deeper interpretation, LC-HRMS testing supports accurate mass measurement, isotope pattern evaluation, and molecular formula proposal for chromatographically resolved components.
For highly complex samples, our 2D chromatography testing approach combines reverse-phase methods with orthogonal separation modes to improve peak capacity and reveal components hidden under co-eluting signals.
Our purification platform supports UV-triggered, mass-directed, and time-window fraction collection, allowing target compounds, impurities, peptides, and intermediates to be isolated with practical recovery and traceable chromatographic evidence.
BOC Sciences applies reverse-phase chromatography across diverse pharmaceutical and biotechnology research samples. Whether the project involves a single purified molecule, a crude reaction mixture, a peptide library, an impurity-rich API sample, or a low-abundance degradation product, our scientists select the chromatographic format and detection strategy according to molecular polarity, hydrophobicity, ionization behavior, sample load, and project objective.
Share your target molecule, crude mixture, chromatogram, or separation challenge. Our analytical team will design a practical RP chromatography strategy for identification, profiling, purification, or method transfer.
We evaluate molecular structure, hydrophobicity, ionizable groups, sample matrix, available material, current chromatograms, and project objectives to determine whether the priority is resolution, speed, loading capacity, recovery, or impurity discovery.
Our scientists screen columns, solvents, additives, pH conditions, gradients, temperature, and detection wavelengths. Where necessary, method development experiments are expanded to compare complementary selectivity and improve peak separation.
When purified material is required, we translate analytical results into preparative conditions, adjust column loading, refine fraction windows, monitor target recovery, and use custom purification services to support downstream use.
We provide chromatograms, conditions, fraction information, peak assignments, recovery summaries, purity estimation, and practical recommendations. For ongoing programs, method transfer support helps align the method with client-side instruments and project workflows.
Co-elution is a frequent barrier in API impurity profiling and peptide sequence analysis. BOC Sciences addresses this challenge by screening complementary stationary phases, adjusting mobile-phase pH, modifying gradient slope, and applying orthogonal detection. Our goal is to transform unresolved shoulders or broad peaks into interpretable chromatographic events that support accurate impurity tracking and informed development decisions.
Basic, acidic, amphiphilic, or highly hydrophobic compounds may show tailing, fronting, adsorption, or poor recovery. We optimize solvent composition, additive selection, sample diluent, injection volume, column temperature, and wash conditions to reduce analyte loss and improve reproducibility. These adjustments are especially valuable for low-abundance impurities, sticky peptides, and complex reaction mixtures.
Peptides often contain deletion sequences, oxidation variants, deamidated products, protecting-group residues, and hydrophobic modifications that complicate separation. BOC Sciences combines wide-pore RP columns, ion-pair strategies, temperature control, and MS-compatible methods to improve selectivity while preserving material for additional characterization or downstream biochemical research.
A well-resolved analytical chromatogram does not automatically translate into successful purification. Our scientists evaluate loading capacity, target concentration, peak spacing, solvent removal, fraction stability, and detector response before scaling the method. This disciplined approach reduces material loss and improves the practicality of isolating compounds for structural confirmation or further development.
Collaborate with BOC Sciences to solve difficult separation, purification, and impurity profiling problems. From rapid analytical screening to preparative isolation, we provide scientifically grounded strategies for complex drug development samples.
Our scientists understand how stationary phase chemistry, analyte hydrophobicity, mobile-phase composition, and detector selection interact. This expertise enables practical solutions for challenging small molecules, peptides, impurities, and complex mixtures.
BOC Sciences connects chromatography testing, purification, structure confirmation, and impurity analysis within one coordinated workflow, reducing the need to transfer fragile samples between disconnected service providers.
UV, MS, HRMS, ELSD, CAD, and fraction-based analysis can be selected according to analyte properties. This flexibility helps reveal components that may be invisible or poorly represented under a single detection mode.
Beyond chromatograms, we deliver clear interpretation, method conditions, peak behavior, fraction guidance, and next-step recommendations, helping chemists and project managers make confident decisions with limited material and tight research timelines.
Client Needs: A peptide research group needed to separate a hydrophobic 32-mer cyclic peptide from deletion variants, oxidized species, and late-eluting protecting-group residues before performing biochemical evaluation.
Challenges: The target peptide and two major impurities eluted within a narrow retention window, while high organic conditions caused broad peaks and inconsistent recovery during repeat injections.
Solution: BOC Sciences screened six wide-pore RP columns, compared formic acid and ammonium-based mobile phases, and tested three gradient slopes under controlled temperature. We then applied LC-MS peak tracking across 24 injections, selected a phenyl-based stationary phase for improved aromatic interaction, and optimized fraction windows to isolate the cyclic peptide from two deletion variants with stable recovery.
Outcome: The optimized method delivered clear separation of the target peptide and major sequence-related impurities, enabling confident fraction collection and downstream biochemical testing.
Client Needs: A pharmaceutical chemistry team observed an unknown impurity in a late-stage intermediate containing a halogenated aromatic core and needed enough isolated material for structural characterization.
Challenges: The impurity showed weak UV response, partial co-elution with the main compound, and poor reproducibility when transferred directly from an analytical scouting method to a semi-preparative column.
Solution: We rebuilt the method using UHPLC-DAD-MS screening, evaluated four organic modifier ratios, and introduced a shallow mid-gradient segment around the impurity region. After confirming the target mass, BOC Sciences performed repeated semi-preparative injections with mass-guided fraction collection, pooled 18 impurity-enriched fractions, removed solvent under mild conditions, and submitted the material for HRMS and NMR-compatible profiling.
Outcome: The unknown impurity was isolated at sufficient quantity for structural interpretation, and the refined method provided a practical monitoring tool for future synthesis optimization.
Client Needs: A drug discovery team required gram-level purification of a lipophilic kinase inhibitor analog from a crude synthesis mixture containing regioisomers and nonpolar coupling by-products.
Challenges: The analytical method separated the target peak but used conditions that generated long cycle times, limited column loading, and excessive solvent consumption during preparative runs.
Solution: BOC Sciences mapped the crude mixture by analytical RP-HPLC, then optimized sample diluent, injection load, and gradient compression for preparative separation. We conducted 12 loading studies, adjusted the final wash to remove nonpolar residues, and used UV-triggered fraction collection followed by pooled purity checks. The workflow balanced throughput, target recovery, and solvent removal practicality.
Outcome: The target analog was purified with improved recovery and a shorter preparative cycle, providing sufficient material for formulation screening and additional structure-activity studies.
Reverse-phase chromatography separates molecules based on hydrophobicity differences. It is suitable for peptides, small-molecule APIs, synthetic intermediates, lipid-related molecules, oligonucleotide derivatives, and certain protein fragments. For samples with closely related structures or minimal polarity differences, reverse-phase chromatography provides high resolution. At BOC Sciences, we select appropriate stationary phases, mobile phases, and gradient conditions based on solubility, hydrophobicity, molecular weight, pKa, and project objectives to achieve optimal separation.
Reverse-phase HPLC emphasizes high resolution, reproducibility, and method control, making it ideal for fine separation and purification of complex drug samples. Compared to precipitation, extraction, or low-resolution column chromatography, reverse-phase HPLC efficiently distinguishes main components, truncated sequences, oxidized forms, deprotected by-products, isomers, and related impurities. For drug development clients, it not only yields purified compounds but also establishes scalable, interpretable, and robust chromatographic methods for process development, characterization, and impurity analysis.
Column and mobile phase selection depends on the molecule’s structure and separation goals. Considerations include stationary phase type (C18, C8, phenyl, or polar-embedded), pH and buffer systems, and organic modifiers such as acetonitrile or methanol affecting peak shape and selectivity. For peptides or oligonucleotides, ion-pairing agents and gradient slope optimization may be necessary. BOC Sciences screens multiple conditions at small scale, evaluates retention, peak shape, resolution, and recovery, and then determines the most suitable chromatography strategy for the project.
Yes. Reverse-phase chromatography is particularly effective for separating structurally similar impurities from the main component, such as truncated or inserted sequences in peptides, oxidation or deamidation by-products, protecting group residues, or related small-molecule synthesis by-products. For challenging samples, BOC Sciences optimizes stationary phase selection, pH, ion-pairing, gradient program, column temperature, and detection method. MS or UV detection can also be integrated to verify target peaks and key impurities for reliable separation.
BOC Sciences provides comprehensive services including method development, condition screening, sample preparation, analytical RP-HPLC, preparative reverse-phase purification, impurity separation, and method optimization. We support small-molecule APIs, peptides, oligonucleotides, lipid derivatives, and complex intermediates. Our services address challenges such as peak overlap, low recovery, poor solubility, complex impurity profiles, and scaling inconsistencies. Deliverables include optimized chromatographic conditions, purified samples, separation profiles, key peak information, and project summaries, giving clients clear guidance for downstream development decisions.
BOC Sciences quickly turned our broad, unresolved peptide chromatogram into a usable method. Their team explained each selectivity decision clearly and gave us practical conditions we could apply across related sequences.
— Curtis, Senior Peptide Scientist
We needed an unknown impurity isolated from a very limited sample. BOC Sciences designed a thoughtful RP-HPLC strategy, tracked the target by MS, and delivered material suitable for deeper characterization.
— Sutton, Analytical Development Manager
The preparative purification workflow was handled with impressive attention to loading, fraction selection, and recovery. Their chromatographic reasoning helped us avoid wasting valuable synthetic material.
— Arnold, Discovery Chemistry Lead
BOC Sciences provided more than chromatograms. We received concise interpretation, method conditions, peak assignments, and next-step recommendations that helped our project team make decisions quickly.
— Franklin, Pharmaceutical Project Manager
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
